VIR vs. CNTA, XENE, CGON, QURE, RARE, APLS, IMVT, GMTX, OGN, and MOR
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Gemini Therapeutics (GMTX), Organon & Co. (OGN), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs. Its Competitors
Centessa Pharmaceuticals (NASDAQ:CNTA) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
Centessa Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -2,895.94%. Centessa Pharmaceuticals' return on equity of -40.39% beat Vir Biotechnology's return on equity.
82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 16.0% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Centessa Pharmaceuticals presently has a consensus price target of $32.38, indicating a potential upside of 41.62%. Vir Biotechnology has a consensus price target of $17.30, indicating a potential upside of 198.28%. Given Vir Biotechnology's higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Centessa Pharmaceuticals.
In the previous week, Vir Biotechnology had 12 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 15 mentions for Vir Biotechnology and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.82 beat Vir Biotechnology's score of 0.50 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.
Centessa Pharmaceuticals has higher earnings, but lower revenue than Vir Biotechnology. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Centessa Pharmaceuticals beats Vir Biotechnology on 11 of the 16 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 10/16/2025 by MarketBeat.com Staff
